HOME | HEADLINES | SKYTOPTV | CONFERENCES | DIGITAL MAGAZINES | TRENDLINE | SURVEYS & POLLS | CONTRIBUTORS | ABOUT US
DIGITAL MAGAZINES
CAPITALISM TODAY ISSUE 2
Editorial Chair
Arthur Kohn, Skytop Contributor Author & Chair of the Editorial Committee
Editorial Committee Members
Lorraine D. Mandel, Founder, Mandel Arbitration and Mediation, LLC
Richard Howitt, Former Member, EU Parliament, Former CEO
Robert L. Tortoriello, Senior Counsel, Cleary Gottlieb
Rhonda Brauer, President & Founder, RLB Governance LLC
Hans Hoogervorst, Former Dutch Finance Minister, Public Policy Expert
ABOUT THIS ISSUE
Capitalism Today
Governance, Capitalism & Our Social Contract
Global experts confront the erosion of trust in institutions—from central banks and democratic media to corporate governance and labor systems—amid rising economic and environmental instability. Voices like Hans Hoogervorst, Arthur Kohn, and Admiral Michael Franken spotlight how financial policy, legal reform, and extreme weather are reshaping national security and public accountability. Through candid conversations with changemakers like Osvald Bjelland, Lord John Browne, Robert Thurman, and Prince Turki Al Faisal, the issue explores the intersection of global leadership, justice movements, and geopolitical transformation.
CAPITALISM TODAY
Editorial Chair
Arthur Kohn, Skytop Contributor Author & Chair of the Editorial Committee
Editorial Committee Members
Lorraine D. Mandel, Founder, Mandel Arbitration and Mediation, LLC
Richard Howitt, Former Member, EU Parliament, Former CEO
Robert L. Tortoriello, Senior Counsel, Cleary Gottlieb
Rhonda Brauer, President & Founder, RLB Governance LLC
Hans Hoogervorst, Former Dutch Finance Minister, Public Policy Expert
ABOUT THIS ISSUE
Capitalism Today
Anticipate & Capitalize on What’s Ahead
Dive into the dynamic world of modern capitalism with unapologetically unbiased analysis and insights on Shareholder Primacy, ESG under fire, takeover law, the intricate economic landscape of the Middle East, transparency in cryptocurrency, and the underlying drivers of biotech & biomedical underperformance.